HRNR and breast carcinoma: The study divided breast cancer tumors into Ki67-high and low groups based on expression levels and found that Ki67-high tumors had a higher percentage of mutations in TP53, TTN, HRNR, MUC16, and AHNAK2 (Additional file 2: Fig. S11).